AR089839A1 - Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular - Google Patents
Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscularInfo
- Publication number
- AR089839A1 AR089839A1 ARP130100264A ARP130100264A AR089839A1 AR 089839 A1 AR089839 A1 AR 089839A1 AR P130100264 A ARP130100264 A AR P130100264A AR P130100264 A ARP130100264 A AR P130100264A AR 089839 A1 AR089839 A1 AR 089839A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- pharmaceutical composition
- hydroxicarbamoil
- distration
- carbamoiloxi
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica caracterizada porque comprende la combinación de cloruro de dietil-[6-(4-hidroxicarbamoil-fenilcarbamoiloximetil)-naftalen-2-il-metil]-amonio o las sales y/o solvatos del mismo aceptables para uso farmacéutico, y al menos un agente activo antiinflamatorio. Reivindicación 2: Una composición farmacéutica de acuerdo a la reivindicación 1, caracterizada porque dicho al menos un agente activo antiinflamatorio es un esteroide, preferentemente un glucocorticoide corticosteroide. Reivindicación 3: Una composición farmacéutica de acuerdo a la reivindicación 2, caracterizada porque dicho al menos un esteroide se selecciona del grupo que consiste en prednisolona, prednisona, deflazacort, hidrocortisona, metilprednisolona, dexametasona, betametasona, triamcinolona, beclometasona, acetato de fludrocortisona, acetato de deoxicorticosterona.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IT2012/000040 WO2013114413A1 (en) | 2012-02-03 | 2012-02-03 | Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089839A1 true AR089839A1 (es) | 2014-09-17 |
Family
ID=45992803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130100264A AR089839A1 (es) | 2012-02-03 | 2013-01-29 | Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular |
Country Status (11)
Country | Link |
---|---|
US (2) | US9421184B2 (es) |
EP (3) | EP2809313A1 (es) |
JP (2) | JP2015512869A (es) |
CN (2) | CN104093403A (es) |
AR (1) | AR089839A1 (es) |
AU (1) | AU2012368818B2 (es) |
BR (1) | BR112014018975A2 (es) |
CA (1) | CA2857082C (es) |
HK (1) | HK1200731A1 (es) |
MX (2) | MX349767B (es) |
WO (1) | WO2013114413A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUB20155193A1 (it) * | 2015-11-03 | 2017-05-03 | Italfarmaco Spa | Sospensioni orali di Givinostat fisicamente e chimicamente stabili |
US11918570B2 (en) | 2020-04-13 | 2024-03-05 | The Research Foundation For The State University Of New York | Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
IT1283637B1 (it) | 1996-05-14 | 1998-04-23 | Italfarmaco Spa | Composti ad attivita' antinfiammatoria ed immunosoppressiva |
ITMI20011733A1 (it) * | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
AU2002348474A1 (en) | 2001-10-18 | 2003-04-28 | The Salk Institute For Biological Studies | Methods of using deacetylase inhibitors to promote cell differentiation and regeneration |
FR2847817B1 (fr) | 2002-11-28 | 2006-11-10 | Centre Nat Rech Scient | Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires |
ITMI20030063A1 (it) | 2003-01-17 | 2004-07-18 | Italfarmaco Spa | Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico. |
FR2898274B1 (fr) | 2006-03-07 | 2008-10-03 | Sod Conseils Rech Applic | Composition contenant des derives d'amidine ou de carboxamide et des steroides a titre de medicament |
WO2008101121A2 (en) * | 2007-02-14 | 2008-08-21 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to promoter regulation by muc1 and klf proteins |
NZ584279A (en) * | 2007-09-19 | 2011-11-25 | 4Sc Ag | Novel tetrahydrofusedpyridines as histone deacetylase inhibitors |
IT1396915B1 (it) | 2009-10-23 | 2012-12-20 | Italfarmaco Spa | Dietil-[6-(4-idrossicarbamoil-fenil-carbamoilossimetil)-naftalen-2-il-metil]-ammonio cloruro ed altri derivati della n-idrossi-benzammide per l'uso nel trattamento di infezioni da hiv. |
IT1397912B1 (it) * | 2010-01-28 | 2013-02-04 | Chemi Spa | Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato. |
US8217079B2 (en) * | 2010-03-26 | 2012-07-10 | Italfarmaco Spa | Method for treating Philadelphia-negative myeloproliferative syndromes |
WO2011127482A2 (en) * | 2010-04-09 | 2011-10-13 | The Salk Institute For Biological Studies | Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto |
-
2012
- 2012-02-03 CN CN201280067188.0A patent/CN104093403A/zh active Pending
- 2012-02-03 MX MX2014009049A patent/MX349767B/es active IP Right Grant
- 2012-02-03 MX MX2017008591A patent/MX370451B/es unknown
- 2012-02-03 CA CA2857082A patent/CA2857082C/en active Active
- 2012-02-03 EP EP12715734.5A patent/EP2809313A1/en not_active Ceased
- 2012-02-03 JP JP2014555390A patent/JP2015512869A/ja active Pending
- 2012-02-03 WO PCT/IT2012/000040 patent/WO2013114413A1/en active Application Filing
- 2012-02-03 EP EP20211172.0A patent/EP3858340A1/en active Pending
- 2012-02-03 EP EP21166210.1A patent/EP3871669A1/en active Pending
- 2012-02-03 CN CN201610833586.9A patent/CN107007580A/zh active Pending
- 2012-02-03 AU AU2012368818A patent/AU2012368818B2/en active Active
- 2012-02-03 BR BR112014018975-7A patent/BR112014018975A2/pt not_active Application Discontinuation
-
2013
- 2013-01-29 AR ARP130100264A patent/AR089839A1/es not_active Application Discontinuation
-
2014
- 2014-07-28 US US14/444,959 patent/US9421184B2/en active Active
-
2015
- 2015-02-06 HK HK15101343.5A patent/HK1200731A1/xx unknown
-
2016
- 2016-02-24 JP JP2016033585A patent/JP6502876B2/ja active Active
- 2016-07-13 US US15/208,957 patent/US9867799B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP6502876B2 (ja) | 2019-04-17 |
EP2809313A1 (en) | 2014-12-10 |
AU2012368818B2 (en) | 2017-11-16 |
US9867799B2 (en) | 2018-01-16 |
BR112014018975A2 (pt) | 2018-05-08 |
CN104093403A (zh) | 2014-10-08 |
JP2016128504A (ja) | 2016-07-14 |
JP2015512869A (ja) | 2015-04-30 |
MX349767B (es) | 2017-08-11 |
CA2857082C (en) | 2019-07-09 |
CN107007580A (zh) | 2017-08-04 |
US9421184B2 (en) | 2016-08-23 |
AU2012368818A1 (en) | 2014-08-21 |
MX2014009049A (es) | 2014-11-25 |
US20160346243A1 (en) | 2016-12-01 |
US20140370089A1 (en) | 2014-12-18 |
MX370451B (es) | 2019-12-13 |
AU2012368818A2 (en) | 2014-08-28 |
EP3858340A1 (en) | 2021-08-04 |
HK1200731A1 (en) | 2015-08-14 |
CA2857082A1 (en) | 2013-08-08 |
WO2013114413A1 (en) | 2013-08-08 |
EP3871669A1 (en) | 2021-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP21001547A (es) | Formulación farmacéutica de odevixibat | |
RS53329B (en) | PROCEDURE AND MIXTURE FOR TREATMENT OF INFLAMMATORY DISORDERS | |
TR201817995T4 (tr) | Nöroakti̇f steroi̇dler ve kullanim yöntemleri̇ | |
BR112012014059A8 (pt) | gel transdérmico de progestina / estradiol. | |
JP2012532889A5 (es) | ||
BR112016021023A8 (pt) | composições de corticosteroides tópicos | |
BR112018069877A2 (pt) | composição farmacêutica de hormônio esteróide | |
BR112014027681B8 (pt) | Nanocristais de propionato de fluticasona, composição tópica farmacêutica compreendendo os mesmos, seu uso e método de fabricação | |
PH12017500239A1 (en) | Abiraterone acetate formulation and methods of use | |
MX2013008543A (es) | Sistema de administracion transdermica de farmacos y metodo para usar el mismo. | |
CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
BR112015024234A2 (pt) | composição de liberação sustentada injetável e método para o uso da mesma para tratar inflamação em articulações e dor associada com a mesma | |
MX2019003685A (es) | Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer. | |
PE20200444A1 (es) | Terapia de combinacion para cancer de prostata | |
AR123674A2 (es) | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona | |
PE20180489A1 (es) | Soluciones de esteroide neuroactivo y sus metodos de uso | |
AR089839A1 (es) | Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular | |
MX2017013795A (es) | Combinaciones terapeuticas de tratamientos antivirales y antiinflamatorios. | |
MX2018009514A (es) | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1. | |
AR096459A1 (es) | Composiciones de corticosteroides y método de fabricación | |
CL2018002287A1 (es) | Derivados de tetrahidroisoquinolina. | |
UY36948A (es) | Formulaciones de corticosteroides para mantener concentraciones de corticosteroide en el líquido sinovial | |
MX2022000747A (es) | Compuestos de estra-1,3,5(10)-trien-17-ona sustituida con 15.beta.-[3-propanamido] y sus 17-oximas para usarse en la inhibicion de 17.beta.-hidroxiesteroides deshidrogenasas. | |
MX2023006235A (es) | Composiciones para administracion de farmacos y metodos de uso de las mismas. | |
JP2015034162A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |